Advertisement

Picture EBD Group ChinaBio Partnering Forum 2025 Shanghai 650x100px
Organisation › Details

SanReno Therapeutics (CN)

SanReno Therapeutics is a leading clinical-stage enterprise specializing in the strategic development, exploration, and commercialization of revolutionary therapies tailored for kidney diseases. Our key assets focus on treating Immunoglobulin A Nephropathy (IgAN). Atrasentan, an oral endothelian A receptor antagonist (ERA), has reached Phase 3 with success in reducing proteinuria. Zigakibart, our anti-APRIL (A Proliferation Inducing Ligand) antibody, received regulatory approval for Phase 3 studies. SanReno is dedicated to delivering transformative medicines for critical unmet needs in kidney disease therapeutics, driving advancements and setting new benchmarks in the field. Established in late 2021 as a joint venture between the investor consortium and Chinook Therapeutics (now part of Novartis), SanReno holds exclusive rights in Greater China and Singapore for two late-stage assets targeting Immunoglobulin A Nephropathy (IgAN): atrasentan and zigakibart. Atrasentan, an oral endothelin A receptor antagonist (ERA), is presently undergoing Phase 3 development for IgAN. It demonstrated clinically meaningful and highly statistically significant proteinuria reduction at the 36-weeks interim analysis, successfully meeting the primary endpoint of its Phase 3 study. Zigakibart (BION-1301), a subcutaneously administered monoclonal antibody targeting APRIL (A Proliferation Inducing Ligand), obtained approval from China CDE for entry into the Phase 3 study in October 2023. *

 

Period Start 2021-12-01 established jv
Person Person Huang, Haoyu (James) (SanReno Therapeutics 202401 CEO before Takeda China + Baxter Greater China + AbbVie Taiwan)
     
Region Region Shanghai
  Country China
  City n. a. Shanghai
    Address record changed: 2024-01-17
     
Basic data Employees n. a.
     
    * Document for »About Section«: SanReno Therapeutics. (1/5/24). "Press Release: SanReno Therapeutics Announces Acquisition by Novartis in Pivotal Transaction to Bring Forward Transformative Therapeutics in Kidney Disease". Shanghai.
     
   
Record changed: 2024-09-22

Advertisement

Picture Kenes Exhibitions Biomed Israel 2025 Tel Aviv 650x200px

More documents for Novartis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Swiss Biotech Association LSA Global Village 2025 Basel 650x300px




» top